Novartis AG Common Stock (NVS)
EBITDA Growth
-2.30%
Quarterly · Period ending:
NVS EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-2.30%period ending
Latest reported-2.30%period ending
NVS Quarterly EBITDA YoY % (-22.06% → -2.30%)
Year-over-year change
High-resolution chart · PNG
NVS ebitda growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Growth |
|---|---|
| -2.3031% | |
| -7.22% | |
| -2.2218% | |
| 4.0435% | |
| 15.7554% | |
| 25.0214% | |
| 24.0555% | |
| 14.9232% | |
| 14.1583% | |
| 1.6122% | |
| 7.0113% | |
| 31.7422% | |
| 13.6431% | |
| 7.3684% | |
| -79.0747% | |
| -24.0942% | |
| -21.4521% | |
| -1.7015% | |
| 326.6849% | |
| 12.2215% | |
| 22.3225% | |
| 1.8501% | |
| 12.2596% | |
| 8.1491% | |
| 8.3912% | |
| 12.1618% | |
| 12.1369% | |
| 4.6814% | |
| -59.586% | |
| 6.8482% | |
| -12.5723% | |
| -6.4704% | |
| 283.4464% | |
| 67.5129% | |
| 29.2073% | |
| 3.9181% | |
| -33.3067% | |
| -45.5453% | |
| 17.7506% | |
| 7.5585% | |
| -1.8282% | |
| -5.6294% | |
| -37.254% | |
| -24.6466% | |
| -14.6836% | |
| 0.3881% | |
| 11.2714% | |
| 29.9867% | |
| 3.7208% | |
| -2.02% | |
| -5.906% | |
| -10.4032% | |
| -4.1002% | |
| 6.0751% | |
| 24.0723% | |
| -7.5651% | |
| -6.3706% | |
| -16.5194% | |
| -4.8932% | |
| 7.4662% | |
| 26.8826% | |
| 7.4141% | |
| -1.8912% | |
| 28.7065% | |
| 21.3806% | |
| 50.9898% | |
| 12.4673% | |
| -2.9316% | |
| -4.8647% | |
| -6.1499% | |
| 50.172% | |
| 12.7546% | |
| 25.2952% | |
| 8.5913% | |
| -25.5397% | |
| 17.8206% | |
| 6.1464% | |
| 15.6476% | |
| -1.7613% | |
| 6.5381% | |
| 15.399% | |
| 26.514% | |
| 12.404% | |
| 16.5608% | |
| 1.564% | |
| 8.985% | |
| 5.0064% | |
| 11.8579% | |
| 20.4338% | |
| 8.9426% | |
| 24.8411% | |
| 23.1494% | |
| 21.4979% | |
| -65.9325% | |
| 119.2555% | |
| -73.3501% | |
| 48.5067% | |
| 9.4144% | |
| 11.3873% | |
| 14.2389% |